Arena Preclinical, Early Data for Olorinab at Crohn’s & Colitis Meet

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present preclinical and early clinical development data from its investigative drug candidate olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal diseases, at the Crohn`s & Colitis Congress in Las Vegas, NV.

Presentation Details:

Title: Olorinab, a Peripherally Restricted, Highly Selective Agonist of the Cannabinoid Receptor Type 2 for the Management of Visceral Pain in Inflammatory Bowel Disease (IBD)Preclinical and Early Clinical Development

Poster Presentation Dates: Thursday, Feb. 7, 7:15PM PST and Friday, Feb. 8, 3:50PM PST

https://www.marketscreener.com/ARENA-PHARMACEUTICALS-IN-35897659/news/Arena-Pharmaceuticals-Presents-Preclinical-and-Early-Clinical-Development-Data-for-Olorinab-at-Cro-27989564/